Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262110366 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Dana P Narvaez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer remains a major global health challenge. In 2022, there were an estimated 2.3 million new cases and 670,000 deaths among women worldwide. Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer accounts for approximately 70% of breast cancer diagnoses. The treatment landscape for advanced HR+)/HER2− breast cancer has been transformed by the introduction of CDK4/6 inhibitors in the first-line setting. However, therapeutic strategies following progression on CDK4/6 inhibitors remain heterogeneous and uncertainty exists in their optimal integration in clinical practice. This review aims to systematically examine available second-line and subsequent treatment options for HR+/HER2− metastatic breast cancer after progression on CDK4/6 inhibitors, with a focus on biomarker-driven strategies and emerging therapies. The therapeutic landscape beyond CDK4/6 inhibitors includes targeted agents guided by actionable biomarkers as well as novel selective estrogen receptor degraders (SERDs). In biomarker-unselected populations, options include CDK4/6 continuation strategies, endocrine monotherapy in selected cases, and cytotoxic therapy. The integration of molecular testing via next-generation sequencing has become standard of care in guiding these decisions. However, overlapping molecular alterations and a lack of consensus on treatment sequencing pose significant challenges. Prognostic factors such as circulating tumor DNA dynamics may further refine treatment personalization. Post-CDK4/6 therapy in HR+/HER2− metastatic breast cancer is an evolving and increasingly complex area of practice. Optimal treatment selection should be tailored to both tumor biology and patient-specific factors, supported by molecular testing and high-quality evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
ORCID-Profile: Dana P Narvaez, David W Cescon
Zitieren
APA
Narvaez, D. P., & Cescon, D. W. (2025). Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110366
Vancouver
Narvaez DP, Cescon DW. Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110366
BibTeX
@article{Narvaez2025,
author = {Narvaez, Dana P and Cescon, David W},
title = {Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262110366}
}
EUVIMED